171 related articles for article (PubMed ID: 27995529)
1. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
Verboom MC; Visser L; Kouwen S; Swen JJ; Diepstraten J; Posthuma WF; Gelderblom H; van Lammeren D; Wilms EB
Pharmacogenet Genomics; 2017 Jun; 27(6):223-226. PubMed ID: 28383355
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
Khan MS; Barratt DT; Somogyi AA
Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
[TBL] [Abstract][Full Text] [Related]
5. Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.
Wang Q; Jiang ZP; Zeng J; Zhu Y; Cai HL; Xiang DX; He Q; Shi XL; Zhong AN; Zhao XL; Xu P
J Pharm Pharm Sci; 2020; 23(1):1-9. PubMed ID: 32027818
[TBL] [Abstract][Full Text] [Related]
6. Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
Adehin A; Adeagbo BA; Kennedy MA; Bolaji OO; Olugbade TA; Bolarinwa RA; Durosinmi MA
Leuk Lymphoma; 2019 Jan; 60(1):216-221. PubMed ID: 29741432
[TBL] [Abstract][Full Text] [Related]
7. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
[TBL] [Abstract][Full Text] [Related]
9. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
10. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
Dalle Fratte C; Gagno S; Roncato R; Polesel J; Zanchetta M; Buzzo M; Posocco B; De Mattia E; Borsatti R; Puglisi F; Foltran L; Guardascione M; Buonadonna A; Cecchin E; Toffoli G
Br J Clin Pharmacol; 2023 Mar; 89(3):1089-1098. PubMed ID: 36178950
[TBL] [Abstract][Full Text] [Related]
12. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations in influx transporter gene
Makhtar SM; Husin A; Baba AA; Ankathil R
J Genet; 2018 Sep; 97(4):835-842. PubMed ID: 30262695
[TBL] [Abstract][Full Text] [Related]
15. Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.
Adattini JA; Adiwidjaja J; Gross AS; McLachlan AJ
Pharmacol Res Perspect; 2023 Aug; 11(4):e01082. PubMed ID: 37417254
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
Ostojic A; Sertic D; Roncevic P; Peric Z; Granic P; Matic N; Basic-Kinda S; Serventi-Seiwerth R; Radman I; Zadro R; Nemet D
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):472-6. PubMed ID: 27245313
[TBL] [Abstract][Full Text] [Related]
17. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.
Wang Q; Jiang ZP; Yu EQ; Zeng J; Zhu Y; Cai HL; Yan M; Xiang DX; Zhao XL; Xu P; Jiao Z; Banh HL
Pharmacogenomics; 2019 Mar; 20(4):251-260. PubMed ID: 30767712
[TBL] [Abstract][Full Text] [Related]
19. Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.
Omran MM; Ibrahim AB; Abdelfattah R; Shouman SA; Hamza MS
Eur J Clin Pharmacol; 2024 Jul; 80(7):1061-1068. PubMed ID: 38536418
[TBL] [Abstract][Full Text] [Related]
20. The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
Van Obbergh F; Knoops L; Devos T; Beguin Y; Graux C; Benghiat F; Kargar-Samani K; Bauwens D; Efira A; Dubois C; Springael C; Montfort L; Connerotte T; Capron A; Delannoy A; Wallemacq P
Clin Biochem; 2017 May; 50(7-8):452-454. PubMed ID: 28017570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
